PPARG and gout: Supporting this mechanism, previous research of pioglitazone, a ligand for PPAR-γ, demonstrated a 19% risk reduction in gout development compared to non-pioglitazone users [30], and diabetic patients using PPAR-γ agonists have exhibited a reduced incidence of gout compared to non-PPAR-γ agonist users.